Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead

Group 1: Pfizer and the Healthcare Sector - Pfizer announced a deal with the U.S. government to avoid tariffs for three years by reducing drug prices and investing in local manufacturing [1] - This deal positively impacted Pfizer and the broader healthcare sector, with expectations of similar agreements in the future [1] Group 2: CRISPR Therapeutics - CRISPR Therapeutics is a gene-editing company with one approved drug, Casgevy, which targets two rare blood diseases and is priced at $2.2 million in the U.S. [4][5] - The company estimates around 60,000 potential patients for Casgevy in the launched countries, indicating future sales potential [5] - Significant clinical progress is anticipated with leading candidates CTX310 and CTX320, which target cardiovascular risk factors and could address up to 40 million patients in the U.S. [6][7] Group 3: BioNTech - BioNTech, alongside CRISPR Therapeutics, has seen stock price increases and possesses significant upside potential due to innovative developments [2][8] - Both companies are positioned well within the biotech sector, with catalysts that could drive stock prices higher in the coming years [8]